Abstract
Immune checkpoint inhibitors targeting the cytotoxic T lymphocyte-associated antigen-4 and programmed cell death-1 receptors have transformed the treatment of melanoma and other cancers. These therapies are associated with a number of side effects, including immune-related adverse events. Sarcoidosis-like granulomas (SLGs) are important immune checkpoint inhibitor-related reactions to recognize as SLGs can mimic disease progression and accordingly impact treatment decisions. We systematically review reports of immune checkpoint inhibitor-induced SLGs in cancer patients and discuss potential underlying pathophysiological mechanisms.
| Original language | English (US) |
|---|---|
| Journal | International Journal of Clinical Oncology |
| DOIs | |
| State | Accepted/In press - Jan 1 2019 |
| Externally published | Yes |
Fingerprint
Keywords
- CTLA-4
- Drug reactions
- Immune checkpoint inhibitor
- Melanoma
- PD-1
- Sarcoidosis-like granuloma
ASJC Scopus subject areas
- Surgery
- Hematology
- Oncology
Cite this
Immune checkpoint inhibitor-induced sarcoidosis-like granulomas. / Rambhia, Pooja H.; Reichert, Barbara; Scott, Jeffrey; Feneran, Ashley N.; Kazakov, Jordan A.; Honda, Kord; Koon, Henry; Gerstenblith, Meg R.
In: International Journal of Clinical Oncology, 01.01.2019.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Immune checkpoint inhibitor-induced sarcoidosis-like granulomas
AU - Rambhia, Pooja H.
AU - Reichert, Barbara
AU - Scott, Jeffrey
AU - Feneran, Ashley N.
AU - Kazakov, Jordan A.
AU - Honda, Kord
AU - Koon, Henry
AU - Gerstenblith, Meg R.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Immune checkpoint inhibitors targeting the cytotoxic T lymphocyte-associated antigen-4 and programmed cell death-1 receptors have transformed the treatment of melanoma and other cancers. These therapies are associated with a number of side effects, including immune-related adverse events. Sarcoidosis-like granulomas (SLGs) are important immune checkpoint inhibitor-related reactions to recognize as SLGs can mimic disease progression and accordingly impact treatment decisions. We systematically review reports of immune checkpoint inhibitor-induced SLGs in cancer patients and discuss potential underlying pathophysiological mechanisms.
AB - Immune checkpoint inhibitors targeting the cytotoxic T lymphocyte-associated antigen-4 and programmed cell death-1 receptors have transformed the treatment of melanoma and other cancers. These therapies are associated with a number of side effects, including immune-related adverse events. Sarcoidosis-like granulomas (SLGs) are important immune checkpoint inhibitor-related reactions to recognize as SLGs can mimic disease progression and accordingly impact treatment decisions. We systematically review reports of immune checkpoint inhibitor-induced SLGs in cancer patients and discuss potential underlying pathophysiological mechanisms.
KW - CTLA-4
KW - Drug reactions
KW - Immune checkpoint inhibitor
KW - Melanoma
KW - PD-1
KW - Sarcoidosis-like granuloma
UR - http://www.scopus.com/inward/record.url?scp=85069503866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069503866&partnerID=8YFLogxK
U2 - 10.1007/s10147-019-01490-2
DO - 10.1007/s10147-019-01490-2
M3 - Review article
C2 - 31321613
AN - SCOPUS:85069503866
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
SN - 1341-9625
ER -